Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG
Hersch et al., 2006 | Neurology | Rct
Citation
Hersch S M, Gevorkian S, ... Rosas H D. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology. 2006-Jan-24;66(2):250-2
Abstract
In a randomized, double-blind, placebo-controlled study in 64 subjects with Huntington disease (HD), 8 g/day of creatine administered for 16 weeks was well tolerated and safe. Serum and brain creatine concentrations increased in the creatine-treated group and returned to baseline after washout. Serum 8-hydroxy-2'-deoxyguanosine (8OH2'dG) levels, an indicator of oxidative injury to DNA, were markedly elevated in HD and reduced by creatine treatment.
Key Findings
Serum 8-hydroxy-2'-deoxyguanosine (8OH2'dG) levels, an indicator of oxidative injury to DNA, were markedly elevated in HD and reduced by creatine treatment.
Outcomes Measured
- Requires manual extraction
Population
| Field | Value |
|---|---|
| Population | huntington disease |
| Sample Size | 64 |
| Age Range | See abstract |
| Condition | See abstract |
MeSH Terms
- 8-Hydroxy-2'-Deoxyguanosine
- Adult
- Biological Availability
- Biomarkers
- Brain
- Creatine
- Deoxyguanosine
- Double-Blind Method
- Female
- Humans
- Huntington Disease
- Male
- Middle Aged
Evidence Classification
- Level: Rct
- Publication Types: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Vertical: creatine-neurological
Provenance
- PMID: 16434666
- DOI: (not available)
- PMCID: Not in PMC
- Verified: 2026-04-09 via PubMed E-utilities API
Source extracted via PubMed E-utilities API on 2026-04-09